The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MDGL | +74.85% | +313.15% | +32.77% | +5,114% |
| S&P | +13.19% | +87.83% | +13.42% | +211% |
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $287.27M | 362.0% |
| Gross Profit | $268.79M | 350.0% |
| Gross Margin | 93.57% | -2.5% |
| Market Cap | $10.22B | 121.9% |
| Market Cap / Employee | $19.36M | 0.0% |
| Employees | 528 | 40.4% |
| Net Income | -$114.19M | -6.8% |
| EBITDA | -$113.62M | 2.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $300.69M | 26.5% |
| Accounts Receivable | $113.29M | 271.9% |
| Inventory | 69.3 | 695.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $345.32M | 192.0% |
| Short Term Debt | $1.08M | 23.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -23.74% | 55.4% |
| Return On Invested Capital | -90.37% | -6.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $78.99M | 216.6% |
| Operating Free Cash Flow | $79.85M | 219.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 8.66 | 9.66 | 9.45 | 14.64 | 145.93% |
| Price to Sales | 37.57 | 23.06 | 13.04 | 13.92 | -76.83% |
| Price to Tangible Book Value | 8.71 | 9.72 | 9.51 | 14.74 | 146.01% |
| Enterprise Value to EBITDA | -89.37 | -83.48 | -129.05 | -84.00 | 161.21% |
| Return on Equity | -80.3% | -50.2% | -36.3% | -41.2% | -68.24% |
| Total Debt | $119.57M | $119.77M | $123.95M | $346.40M | 190.75% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
